PromarkerD is a predictive diagnostic test for diabetic kidney disease and is patented in both Singapore and China.
A new Frost & Sullivan independent report has identified PromarkerD as the world leader with high adoption potential across the Asia Pacific.
This follows news that the PromarkerD technology has been validated by the peer-reviewed scientific journal EuPA Open Proteomics.
Dr Richard Lipscombe, managing director, commented: “PromarkerD means we can accurately predict if someone will get the disease in the next 4 years so they can take lifestye and medication action immediately to cut their risks.”
Results have shown PromarkerD can correctly predict 95% of the previously kidney disease-free diabetic patients who go on to develop chronic kidney disease.
There is currently no available test for predicting the onset of diabetic kidney disease and Frost &
Sullivan suggests Proteomics is one of only two companies worldwide developing such a test.
Proteomics is rated at the forefront of using proteomics technology for diabetes diagnostics worldwide, and has already been granted patents for PromarkerD in China, Singapore, Russia, Australia and the U.S.
The Asian market represents a large scale opportunity for Proteomics as there are 231 million people living with diabetes in Asia alone, according to the International Diabetes Federation.
Worldwide this number is forecast to rise to 642 million people by 2040, and 214 million people are predicted to get chronic kidney disease as a result.
Kidney disease is one of the major complications of diabetes and affects circa one-third of all adult diabetics.
Keeping people alive on dialysis costs more than $100,000 per person per year and globally the diabetes epidemic cost health systems $673 billion dollars in 2015.
PromarkerD provides countries and the world with a potential solution to this costly disease.
Shares are up 14% intra-day currently trading at $0.20.
Proteomics is a medical technology company focused on three integrated areas:
- Diagnostics: biomarkers of disease and personalised medicine;
- Analytical services: specialist contract research fee-for-service model; and
- Drug discovery: therapeutic peptide drug discovery.
Find out more from Richard Lipscombe at Proactive's CEO Sessions.
Click on city below to register by email